

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau(43) International Publication Date  
15 April 2004 (15.04.2004)


PCT

(10) International Publication Number  
WO 2004/030524 A2

- (51) International Patent Classification<sup>7</sup>: A61B (72) Inventor; and  
(21) International Application Number: PCT/US2003/031493 (75) Inventor/Applicant (for US only): HOLLANDER, Eric [US/US]; 380 Orienta Avenue, Manaroneck, NY 10543 (US).  
(22) International Filing Date: 3 October 2003 (03.10.2003) (74) Agent: McCALLUM, Jennifer, M.; The Mccallum Law Firm, LLC, 132 Kolar Court, Erie, CO 80516 (US).  
(25) Filing Language: English (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.  
(26) Publication Language: English (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).  
(30) Priority Data: 60/415,837 3 October 2002 (03.10.2002) US  
(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application: US 60/415,837 (CIP) Filed on 3 October 2002 (03.10.2002)  
(71) Applicant (for all designated States except US): PR PHARMACEUTICALS [US/US]; 1716 Heath Parkway, Fort Collins, CO 80524 (US).

[Continued on next page]

(54) Title: TREATMENT OF AUTISM AND SIMILAR DISORDERS



(57) Abstract: Methods of treating certain behavioral characteristics associated with autism are provided. Additionally, methods of treating disorders associated with repetitive behaviors, social deficits and/or cognitive deficits are also provided. A therapeutic amount of oxytocin or oxytocin analogs, either alone or in combination, are administered to individuals demonstrating behavioral characteristics associated with autism or other disorders to reduce the severity of the debilitating behavior. In various aspects, characteristics such as deficit in social awareness or cognitive skills and repetitive behaviors are treated. Co-administration of oxytocin and/or oxytocin analogs with known psychopharmacologic agents is also provided. Advantageously, oxytocin and oxytocin analogs do not have deleterious effects with other drugs such that administration results in few side effects.



**Declaration under Rule 4.17:**

— *of inventorship (Rule 4.17(iv)) for US only*

**Published:**

— *without international search report and to be republished  
upon receipt of that report*

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*